Ocular Therapeutix™ Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease,

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative the …, Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative the …, Read More

Scroll to Top